Monday, September 10, 2018 The CCTG PA.7 trial: A Randomized Phase II Trial of Gemcitabine and Nab-Paclitaxel vs Gemcitabine, Nab-Paclitaxel, Durvalumab and Tremelimumab as 1st Line Therapy in Metastatic Pancreatic Adenocarcinoma met its target accrual of 180 patients on 26-JUL-2018 and is now officially closed to accrual. The Canadian Cancer Trials Group (CCTG), PA.7 clinical trial combines cutting-edge immunotherapy drugs with standard chemotherapy – a successful mix for treating certain cancers such as kidney and lung – to treat pancreatic cancer, which has the lowest survival rate of all. For more information please contact Lisa Gallinaro, Study Coordinator
